RFG
TGTX icon

RFP Financial Group’s TG Therapeutics TGTX Stock Holding History

RFP Financial Group’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,000
Closed -$17.1K – 944
2023
Q4 		$17.1K Hold
1,000
– – 0.01% 328
2023
Q3 		$8.36K Hold
1,000
– – ﹤0.01% 414
2023
Q2 		$24.8K Buy
+1,000
New +$25.8K 0.01% 292
2023
Q1 		– Sell
-1,000
Closed -$11.8K – 847
2022
Q4 		$11.8K Buy
+1,000
New +$7.26K 0.01% 364

Other funds holding TGTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

RFP Financial Group's TGTX Position: Q1 2024 in Review

RFP Financial Group sold out of TG Therapeutics (TGTX) in Q1 2024, closing a stake of 1,000 shares — an estimated $17.1K sold.

RFP Financial Group first reported a position in TGTX in Q4 2022 and held it in 4 quarters. The position peaked at $24.8K in Q2 2023. 243 funds tracked by Wall St. Rank hold TGTX as of Q1 2024.

  • RFP Financial Group reported no remaining TG Therapeutics position as of Q1 2024 after selling out during the quarter.
  • RFP Financial Group sold 1,000 TG Therapeutics shares in Q1 2024, an estimated $17.1K.
  • RFP Financial Group first reported a position in TG Therapeutics in Q4 2022 and held it in 4 quarters.
  • RFP Financial Group's TG Therapeutics position peaked at $24.8K in Q2 2023.
  • 243 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2024.

Based on RFP Financial Group's 13F filing for Q1 2024, filed 9 May 2024.